Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 2743614, 7 pages
http://dx.doi.org/10.1155/2016/2743614
Research Article

CXCR3, CCR5, and CRTH2 Chemokine Receptor Expression in Lymphocytes Infiltrating Thyroid Nodules with Coincident Hashimoto’s Thyroiditis Obtained by Fine Needle Aspiration Biopsy

1Third Medical Department, The First Faculty of Medicine, Charles University and The General University Hospital in Prague, 128 08 Prague, Czech Republic
2Institute of Medical Biochemistry and Laboratory Diagnostics, The First Faculty of Medicine, Charles University and The General University Hospital in Prague, 128 08 Prague, Czech Republic
3Division of Internal Medicine, University Hospital of Basel, 4031 Basel, Switzerland

Received 14 March 2016; Revised 19 May 2016; Accepted 23 May 2016

Academic Editor: Mahboobeh Mahdavinia

Copyright © 2016 Jan Jiskra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Nagayama, “Animal models of Graves' hyperthyroidism,” Endocrine Journal, vol. 52, no. 4, pp. 385–394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Ajjan, P. F. Watson, and A. P. Weetman, “Detection of IL-12, IL-13, and IL-15 messenger ribonucleic acid in the thyroid of patients with autoimmune thyroid disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 2, pp. 666–669, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. A. P. Weetman, “Cellular immune responses in autoimmune thyroid disease,” Clinical Endocrinology, vol. 61, no. 4, pp. 405–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Myśliwiec, A. Krętowski, J. Topolska et al., “Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids,” Hormone and Metabolic Research, vol. 33, no. 12, pp. 739–743, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Díez, A. Hernanz, S. Medina, C. Bayón, and P. Iglesias, “Serum concentrations of tumour necrosis factor-alpha (TNF-α) and soluble TNF-α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function,” Clinical Endocrinology, vol. 57, no. 4, pp. 515–521, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Rotondi, E. Lazzeri, P. Romagnani, and M. Serio, “Role for interferon-γ inducible chemokines in endocrine autoimmunity: an expanding field,” Journal of Endocrinological Investigation, vol. 26, no. 2, pp. 177–180, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, and P. Romagnani, “Role of chemokines in endocrine autoimmune diseases,” Endocrine Reviews, vol. 28, no. 5, pp. 492–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Aust, D. Sittig, M. Steinert, P. Lamesch, and T. Lohmann, “Graves' disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes,” Clinical and Experimental Immunology, vol. 127, no. 3, pp. 479–485, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Romagnani, M. Rotondi, E. Lazzeri et al., “Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' Disease,” American Journal of Pathology, vol. 161, no. 1, pp. 195–206, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Ruffilli, S. M. Ferrari, M. Colaci et al., “CXCR3 and CXCL10 in autoimmune thyroiditis,” Clinica Terapeutica, vol. 165, no. 3, pp. e237–e242, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Rotondi, A. Falorni, A. De Bellis et al., “Elevated serum interferon-γ-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 4, pp. 2357–2363, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Rotondi and L. Chiovato, “The chemokine system as a therapeutic target in autoimmune thyroid diseases: a focus on the interferon-γ inducible chemokines and their receptor,” Current Pharmaceutical Design, vol. 17, no. 29, pp. 3202–3216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Samson, O. Labbe, C. Mollereau, G. Vassart, and M. Parmentier, “Molecular cloning and functional expression of a new human CC-chemokine receptor gene,” Biochemistry, vol. 35, no. 11, pp. 3362–3367, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Ghorban, M. Dadmanesh, G. Hassanshahi et al., “Is the CCR5 Δ32 mutation associated with immune system-related diseases?” Inflammation, vol. 36, no. 3, pp. 633–642, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. F.-J. Cheng, X.-J. Zhou, Y.-F. Zhao, M.-H. Zhao, and H. Zhang, “Chemokine receptor 5 (CCR5) delta 32 polymorphism in lupus nephritis: a large case-control study and meta-analysis,” Autoimmunity, vol. 47, no. 6, pp. 383–388, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Watanabe, N. Yamamoto, H. Maruoka, F. Matsuzuka, A. Miyauchi, and Y. Iwatani, “Relation of CD30 molecules on T-cell subsets to the severity of autoimmune thyroid disease,” Thyroid, vol. 13, no. 3, pp. 259–263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Mutalithas, C. Guillen, C. Day, C. E. Brightling, I. D. Pavord, and A. J. Wardlaw, “CRTH2 expression on T cells in asthma,” Clinical and Experimental Immunology, vol. 161, no. 1, pp. 34–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Gosset, F. Bureau, V. Angeli et al., “Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells,” The Journal of Immunology, vol. 170, no. 10, pp. 4943–4952, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Nagata and H. Hirai, “The second PGD2 receptor CRTH2: structure, properties, and functions in leukocytes,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 69, no. 2-3, pp. 169–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. M. L. Fajt, S. L. Gelhaus, B. Freeman et al., “Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation,” Journal of Allergy and Clinical Immunology, vol. 131, no. 6, pp. 1504–1512, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Liu, M. Zheng, J. Qiao, Y. Dang, P. Zhang, and X. Jin, “Role of prostaglandin D2/CRTH2 pathway on asthma exacerbation induced by Aspergillus fumigatus,” Immunology, vol. 142, no. 1, pp. 78–88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Simchen, I. Lehmann, D. Sittig, M. Steinert, and G. Aust, “Expression and regulation of regulated on activation, normal T cells expressed and secreted in thyroid tissue of patients with Graves' disease and thyroid autonomy and in thyroid-derived cell populations,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4758–4764, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-H. Lee, Y. Kim, J.-W. Choi, and Y.-S. Kim, “The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis,” European Journal of Endocrinology, vol. 168, no. 3, pp. 343–349, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. K. W. Kim, Y. J. Park, E. H. Kim et al., “Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis,” Head and Neck, vol. 33, no. 5, pp. 691–695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Zhang, F. Y. Meng, W. L. Li, C. X. Zhou, Z. Guan, and H. Y. Fan, “Association of chemotactic factor receptor 5 gene with breast cancer,” Genetics and Molecular Research, vol. 12, no. 4, pp. 5289–5300, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Tamaru, B. Matsuura, and M. Onji, “Increased levels of serum interleukin-12 in Graves' disease,” European Journal of Endocrinology, vol. 141, no. 2, pp. 111–116, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Kimura, S.-C. Tzou, R. Rocchi et al., “Interleukin (IL)-12-driven primary hypothyroidism: the contrasting roles of two Th1 cytokines (IL-12 and interferon-γ),” Endocrinology, vol. 146, no. 8, pp. 3642–3651, 2005. View at Publisher · View at Google Scholar · View at Scopus